Skip to main content

Table 1 Patient baseline characteristics, efficacy population

From: Effectiveness of combination therapy with nifedipine GITS: a prospective, 12-week observational study (AdADOSE)

Characteristic n (%)
Patients, n (%) 3430 (100)
Gender, n (%)  
 Male 1993 (58.1)
 Female 1387 (40.4)
Mean age, years ± SD (range); n = 3322 53.4 ± 10.4 (19.0–89.0)
Age, n (%)  
 <65 years 2836 (82.7)
 ≥65 years 486 (14.2)
Race, n (%)  
 Asian 1212 (35.3)
 White 966 (28.2)
 Black 96 (2.8)
 Other 970 (28.3)
Mean BMI, kg/m2 ± SD (range); n = 3214 29.9 ± 5.2 (15.1–57.4)
Mean BP, mm Hg ± SD (range)  
 SBP [n = 3413] 166.4 ± 16.7 (100.0–260.0)
 DBP [n = 3418] 99.7 ± 9.9 (55.0–170.0)
Stages of hypertension, n (%)a  
 Normal 8 (0.2)
 High normal 16 (0.5)
 Grade 1 (mild) 407 (11.9)
 Grade 2 (moderate) 1620 (47.2)
 Grade 3 (severe) 1142 (33.3)
 Isolated systolic hypertension 218 (6.4)
Duration of hypertension, n (%); n = 3426  
 Newly diagnosed 479 (14.0)
 Previously diagnosed 2947 (85.9)
  <1 year 434 (14.7)
  1–5 years 1210 (41.1)
  6–10 years 692 (23.5)
  >10 years 554 (18.8)
Previous antihypertensive therapy, n (%)  
 0 421 (12.3)
 1 1314 (38.3)
 2 1067 (31.1)
 ≥3 521 (15.2)
Previous classes of antihypertensive therapy, n (%); n = 2922b  
 ACE inhibitors 1210 (41.4)
 ARBs 833 (28.5)
 CCBsc 348 (11.9)
 β-blockers 1389 (47.5)
 Thiazide diuretics 940 (32.2)
 Other 97 (3.3)
Smoking history, n (%)  
 Current smoker 725 (21.1)
 Never 1940 (56.6)
 Past smoker 606 (17.7)
  1. Data for all variables were not available for all patients
  2. ACE angiotensin-converting enzyme, ARBs angiotensin II receptor blockers, BMI body mass index, CCBs calcium channel blockers, DBP diastolic blood pressure, GITS gastrointestinal therapeutic system, SBP systolic blood pressure, SD standard deviation
  3. aDefinitions according to ESH/ESC 2007 guidelines. bMultiple responses possible. cOther than nifedipine GITS